Instrumentation Laboratory Reports Record Worldwide Sales In 2014

BEDFORD, Mass., April 13, 2015 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced total worldwide sales in 2014 of $764.4 M US (€587.7 M). In its two major business segments, Hemostasis and Critical Care Diagnostics, IL achieved significant growth of 8.6% and 7.0%, respectively, in local currencies.  Additionally in 2014, the Company shipped a record number of its flagship ACL TOP Hemostasis Testing Systems and GEM Premier 4000 Critical Care Systems globally.

Contributing to the success of IL in 2014 was the significant growth achieved across every key global territory. Other success factors include: completion of the Company's full transition to a direct business model for its Hemostasis product line globally, with the addition of the Japanese market; significant new business contracts signed with large Group Purchasing Organizations, lab networks, and regional hospital consortiums throughout the world; and, increased customer demand for its ACL TOP and GEM Premier product lines.

"In today's changing and challenging healthcare environment, our customers need products that not only enhance efficiency in laboratory testing, but also improve quality of care and patient experience, while lowering the total cost of care. Fortunately, that is exactly what our innovative product solutions deliver," said Ramon Benet, CEO at IL. "Our growth in analyzer placements and increased sales from small hospital labs to large hospital networks, all over the world, attest to the value customers place on IL products, services and support teams. We look forward to introducing more Hemostasis and Critical Testing breakthroughs in 2015 and beyond."     

For more than three decades, IL has led the Hemostasis market through innovation, and today, remains the market leader and the number one manufacturer of Hemostasis instruments and reagents, providing direct support in all key territories worldwide. The ACL TOP Family of Testing Systems is the primary driver of growth in the Hemostasis segment, offering a standardized platform for efficiency and flexibility. The ACL TOP Family includes: ACL TOP 300 CTS, ACL TOP 500 CTS and ACL TOP 700/CTS/LAS models.

Instrumentation Laboratory Reports Record Worldwide Sales in 2014

Complementing the ACL TOP platform is the Company's comprehensive HemosIL® assay menu. In addition to tests for general screening, HemosIL D-Dimer assays for the exclusion of Venous Thromboembolism and HemosIL Liquid Anti-Xa assay for monitoring Heparin treatment, IL also offers a complete line of Specialty testing assays for the diagnosis and management of bleeding and thrombotic disorders. In 2014, IL introduced novel reagents, including HemosIL Direct Thrombin Inhibitor (DTI) Assay for the measurement of dabigatran (Pradaxa), a direct oral anticoagulant (DOAC). Assays for other DOACs are in development and will be released in the coming months. Additionally, the ACL AcuStar® system, the first chemiluminescent immunoassay analyzer, continues to deliver full automation to Specialty Hemostasis testing, including assays for Antiphospholipid Syndrome, Heparin-Induced Thrombocytopenia and von Willebrand Disease.   

In Critical Care diagnostics, sales of the Company's flagship GEM Premier 4000 system achieved record levels, while GEM Premier 3000/3500 systems continued to grow steadily throughout the world. Both systems feature Intelligent Quality Management (iQM®), the first and only automated, active total quality management system. In addition, GEMweb® Plus Custom Connectivity software, a significant asset in the Company's success, offers lab managers complete control of their analyzers from any PC or GEM Premier system, operator certification and advanced regulatory management. 

Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The Company's product lines include Critical Care systems, Hemostasis systems and Information Management systems. IL's GEM® product offerings, part of the Critical Care line, include the GEM Premier™ 4000 analyzer with Intelligent Quality Management (iQM^®), GEM Premier 3500, GEMweb® Plus Custom Connectivity, and complementary products GEM PCL Plus, a portable coagulation analyzer, GEM OPL CO-Oximeter, and GEMdraw arterial blood samplers. The IL Hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, comprised of the ACL TOP 700, ACL TOP 700 LAS, ACL TOP 700 CTS, ACL TOP 500 CTS and ACL TOP 300 CTS. IL also offers the ACL AcuStar®, ACL ELITE®, and other Hemostasis analyzers, along with the comprehensive HemosIL® line of reagents. IL is based in Bedford, Massachusetts. 

The Instrumentation Laboratory logo, GEM, GEMweb, iQM, HemosIL, ACL TOP, ACL ELITE, ACL AcuStar and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.

Logo - http://photos.prnewswire.com/prnh/20140204/NE58020LOGO

SOURCE Instrumentation Laboratory

Related Links

www.ilus.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED